A game-changer in dermatology

17MarMarch 17, 2025

[videojs_video url=’https://du7x25at22z7c.cloudfront.net/IV_BOT_250310_HowieMcKibbon/single_720p.mp4′ poster=’http://www.finnewsnetwork.com.au/newssystem/seqcmsfiles/2025/03/DvozQAF5idb8Nvm0z38e_1920x1080_13406.jpg’]

Dr Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT), discusses the FDA approval and market success of Sofdra, the first new chemical entity approved for primary axillary hyperhidrosis. Launched in the US in February 2024, the treatment has seen strong prescription growth, supported by extensive insurance coverage and a high-performing sales team. The company’s strategy focuses on patient adherence, facilitated by automatic prescription refills and co-pay assistance. A newly launched digital marketing initiative aims to reach millions searching for online treatment options.

Source: Finance News Network

04JulJuly 4, 2021

SUDA Pharmaceuticals (ASX:SUD) acquires invariant natural killer T (iNKT) cell therapy platform, June 2021

01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.

16MayMay 16, 2024

Hazer Group CEO Glenn Corrie on future prospects for innovating hydrogen

16 May 2024 - Glenn Corrie, CEO of Hazer Group, speaks about their groundbreaking low-emission hydrogen and graphite production technology, recent achievements, and future plans for commercialization and global expansion.

21JunJune 21, 2022

BluGlass (ASX:BLG) ships prototype products

21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.

28AugAugust 28, 2021

Chimeric Therapeutics (ASX:CHM) – bringing cell therapy to more patients with cancer, August 2021

26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.

06SepSeptember 6, 2023

Sequoia Financial Group (ASX:SEQ) discusses FY23 results

06 Sep 2023 - Sequoia Financial Group Limited (ASX:SEQ) CEO and Managing Director Garry Crole discusses financial highlights, drivers of growth and revenue going forward, M&A, and cash deployment.

01AugAugust 1, 2021

BARD1 Life Sciences (ASX:BD1) – detecting cancer earlier to save lives, July 2021

29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.

03JunJune 3, 2021

Market update with Shaw and Partners, June 2021

03 Jun 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses measures of growth, inflationary pressures, and similarities between post-war environments and the current economic situation.

27FebFebruary 27, 2020

NetLinkz (ASX:NET) agreement to monitor water quality in Sichuan Province

27 Feb 2020 - NetLinkz Limited (ASX:NET) Executive Chairman and CEO, James Tsiolis talks about the significance of the company's agreement to provides its Virtual Secure Network to a World Bank-sponsored initiative to improve water sanitation services in selected areas of the Deyang Municipality of Sichuan Province.

29JulJuly 29, 2022

INOVIQ (ASX:IIQ) discusses US milestones

29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly results, and the year ahead.

10MarMarch 10, 2025

Immunotherapy and autoimmune diseases: A promising new approach

10 Mar 2025 - Addressing Chronic Conditions with Targeted Treatments

A game-changer in dermatology